X

Trial Profile

Impact of M184V on the Virological Efficacy to Lamivudine/Dolutegravir

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir/lamivudine (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms LAMRES

Most Recent Events

09 Feb 2023 Status changed from recruiting to completed.
30 Oct 2021 Results (n=695) assessing the risk of virologic failure in a large cohort of virologically suppressed persons living with HIV (PLWH) with or without past M184V switched to DTG-3TC in the French DAT AIDS cohort, presented at the 18th European AIDS Conference.
21 Jul 2021 Planned End Date changed from 31 Dec 2020 to 15 Dec 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com